Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.46 |
| ▸ | MASP2 | O00187 | 1/20 | 0.45 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2161684 | 0.85 | TRPV1 (0.40) | RAB9AMAPT | |
| SCHEMBL2162528 | 0.85 | SCN10A (0.52) | PDE10ANPY5RSCN2ARAB9AMAPT | |
| SCHEMBL23585772 | 0.79 | NPY5R (0.47) | PDE10ANPY5RSCN2AMASP2KLK1 | |
| SCHEMBL2161813 | 0.79 | RIPK1 (0.53) | SCN2ARAB9AMAPT | |
| SCHEMBL2153682 | 0.79 | SCN2A (0.55) | PDE10ANPY5RSCN2AMASP2HPGDS | |
| SCHEMBL26733433 | 0.78 | PDE10A (0.53) | PDE10ANPY5RSCN2AMASP2HPGDS | |
| SCHEMBL2153966 | 0.77 | BCHE (0.49) | PDE10ANPY5RSCN2AMASP2ACP1 | |
| SCHEMBL7222077 | 0.75 | EGFR (0.52) | PDE10ANPY5RSCN2AMASP2 | |
| SCHEMBL21376457 | 0.75 | MMP1 (0.43) | RAB9AMAPTMMP1MMP3MMP7 | |
| SCHEMBL1501814 | 0.73 | PDE10A (0.60) | PDE10ANPY5RSCN2AMASP2HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513064-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS | UNIV LEUVEN KATH (BE) | 2018-07-04 | — | — | EP | claimed |
| US-8906915-B2 | Compounds, compositions, and methods for controlling biofilms | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2014-12-09 | — | — | US | claimed |
| US-20130029981-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-01-31 | — | — | US | claimed |
| EP-2513064-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-10-24 | — | — | EP | claimed |
| WO-2011080132-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING BIOFILMS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2011-07-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029981-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | AZI2, NOD1, AADAC | PDE10A 1550/4885NPY5R 1660/4885SCN2A 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.